Anti-PD1 ‘SHR-1210ʹ aberrantly targets pro-angiogenic receptors and this polyspecificity can be ablated by paratope refinement

Monoclonal anti-programmed cell death 1 (PD1) antibodies are successful cancer therapeutics, but it is not well understood why individual antibodies should have idiosyncratic side-effects. As the humanized antibody SHR-1210 causes capillary hemangioma in patients, a unique toxicity amongst anti-PD1...

Descripción completa

Detalles Bibliográficos
Autores principales: Finlay, William J.J., Coleman, James E., Edwards, Jonathan S., Johnson, Kevin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343799/
https://www.ncbi.nlm.nih.gov/pubmed/30541416
http://dx.doi.org/10.1080/19420862.2018.1550321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343799/
https://www.ncbi.nlm.nih.gov/pubmed/30541416
http://dx.doi.org/10.1080/19420862.2018.1550321

Ejemplares similares